{"title":"Glofitamab (Columvi)治疗弥漫性大b细胞淋巴瘤。","authors":"","doi":"10.58347/tml.2023.1682b","DOIUrl":null,"url":null,"abstract":"Glofitamab-gxbm (Columvi – Genentech), a bispecific CD20-directed CD3 T-cell engager, has received accelerated approval from the FDA for IV treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, or large B-cell lymphoma (LBCL) arising from follicular lymphoma after ≥2 lines of systemic therapy.","PeriodicalId":54742,"journal":{"name":"Medical Letter on Drugs and Therapeutics","volume":null,"pages":null},"PeriodicalIF":1.4000,"publicationDate":"2023-08-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Glofitamab (Columvi) for diffuse large B-cell lymphoma.\",\"authors\":\"\",\"doi\":\"10.58347/tml.2023.1682b\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Glofitamab-gxbm (Columvi – Genentech), a bispecific CD20-directed CD3 T-cell engager, has received accelerated approval from the FDA for IV treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, or large B-cell lymphoma (LBCL) arising from follicular lymphoma after ≥2 lines of systemic therapy.\",\"PeriodicalId\":54742,\"journal\":{\"name\":\"Medical Letter on Drugs and Therapeutics\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":1.4000,\"publicationDate\":\"2023-08-07\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Medical Letter on Drugs and Therapeutics\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.58347/tml.2023.1682b\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Medical Letter on Drugs and Therapeutics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.58347/tml.2023.1682b","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
Glofitamab (Columvi) for diffuse large B-cell lymphoma.
Glofitamab-gxbm (Columvi – Genentech), a bispecific CD20-directed CD3 T-cell engager, has received accelerated approval from the FDA for IV treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, or large B-cell lymphoma (LBCL) arising from follicular lymphoma after ≥2 lines of systemic therapy.
期刊介绍:
The Medical Letter, Inc. is committed to providing objective, practical, and timely information on drugs and treatments of common diseases to help our readers make the best decisions for their patients—without the influence of the pharmaceutical industry.
The Medical Letter On Drugs and Therapeutics is a biweekly publication that provides:
Evidence-based, peer-reviewed evaluations of new FDA-approved drugs with conclusions reached by a consensus of experts
New information on previously approved drugs including pivotal clinical trials, new indications, and safety warnings
Consensus recommendations for the preferred and alternative treatments for common disorders
Comparative reviews of drugs for a given indication with particular attention to clinical efficacy, adverse effects, drug interactions, and cost.